Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis
Oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to completion of (or withdrawal from) chemotherapy.
Colorectal Cancer
DRUG: Avastin/FOLFIRI|DIETARY_SUPPLEMENT: Curcumin
Progression-free survival, The primary end point of this study is to evaluate progression-free survival in colorectal cancer patients with unresectable metastasis after treatment with first line Avastin/FOLFIRI in combination with a dietary supplement of nanostructured lipid curcumin particle (Aju Pharm, Korea), which improved biotransformation and bioavailability profiles of curcumin., 2 years
Overall survival rate, Overall survival will be measured in months. Overall survival will be measured in months. Overall survival will be measured in months. Overall survival will be measured in months., 3 years|Overall response rate, According to RECIST criteria v1.1, 2 years|Safety (assessed by toxicity grades defined by NCI-CTCAE (version 4.0), Safety as assessed by toxicity grades defined by NCI-CTCAE (version 4.0), 2 years|Quality of life (QoL), QoL measured by the FACT-G (version 4, Korean version), 2 years|Fatigue (FACIT-Fatigue scale (version 4, Korean version), Fatigue measured by the FACIT-Fatigue scale (version 4, Korean version), 2 years
Oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to completion of (or withdrawal from) chemotherapy.